- 7.16.2025
- News
RFK Jr. and other Trump officials embrace psychedelics after FDA setback
RFK Jr. and former Trump officials are backing psychedelic therapies like MDMA and ibogaine, pushing for FDA approval amid growing bipartisan interest. The article highlights veteran voices, including VETS' Marcus Capone, advocating for access despite safety concerns.
- 7.2.2025
- News
Advocate reacts to Texas governor signing psychedelic research bill into law
An advocate featured by KXAN celebrates Texas’s new legislation as a turning point—allocating $50 million in public funding for ibogaine clinical trials to address PTSD, addiction, and brain injury. She highlights the significance of this support for veterans and first responders.
- 7.2.2025
- News
Why Veterans With PTSD Are Turning to Psychedelics
Veterans are increasingly exploring psychedelic treatments—like ketamine, psilocybin, MDMA, and ibogaine—to heal from PTSD. These therapies tend to be used in guided, clinically-informed settings, with some programs even including spouses for shared healing. Although ibogaine remains illegal in the U.S., many veterans are traveling abroad, driven by promising early results
- 7.2.2025
- News
‘Psychedelics and the Texas Trip’ explores science & history behind state-funded research initiative
Texas recently approved $50 million in public funding, matched privately, to study ibogaine—a plant-derived psychedelic—as a potential treatment for PTSD, TBI, addiction, and related conditions. The initiative is facilitated through a public–private partnership and includes protections to ensure future therapy revenues fund veterans’ programs
- 7.2.2025
- News
Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing
Texas is the first state to fund clinical trials of ibogaine, investing $50 million in public funds to explore its potential for treating PTSD, addiction, and TBI—with future revenues supporting veterans’ programs.